Gilead and Merck Announce Phase 2 Islatravir and Lenacapavir Data
Gilead Sciences and Merck have announced positive results from a Phase 2 clinical trial investigating a novel combination therapy...
Clesrovimab Significantly Reduces RSV in Infants
Merck, known as MSD outside of the United States and Canada, announced positive results from their Phase 2b/3 clinical...
Actineer Begins Actinium-225 Production
Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has successfully produced Actinium-225 (Ac-225) by irradiating...
How AI is Transforming RBQM in Clinical Trials
A recent virtual summit hosted by Cyntegrity focused on the pivotal role of artificial intelligence (AI) in Risk-Based Quality...
Resposne Pharmaceuticals Initates RDX-002 Phase 2 Study Weight management
Response Pharmaceuticals, a clinical-stage company specializing in weight management and metabolic health, has begun enrolling participants in a Phase...
Terray Therapeutics Raises $120M in Series B Funding
Terray Therapeutics, a biotechnology company revolutionizing small molecule drug development, has secured $120 million in Series B funding. This...
Verastem Presents Positive Updated Data for Atutometinib
Verastem Oncology, a company dedicated to developing cancer treatments, has released promising data from its Phase 2 RAMP 201...
Expert Strategies for FDA LDT Compliance: Meeting the 1st Milestone
Clinical laboratories face a critical deadline: achieving Phase One compliance with the FDA’s Laboratory Developed Test (LDT) rule by...
Charles River Launches New Retrogenix® Protein Library
Charles River Laboratories International, Inc. has introduced the Retrogenix® Non-Human Protein Library, a tool designed to assist biopharmaceutical companies...
AN2 Receives Grant for Boron-Based Therapies for Tuberculosis
AN2 Therapeutics, a biopharmaceutical company specializing in boron chemistry-based therapeutics, has secured continued research funding from the Bill &...